A Phase 2/3 interventional study of zatolmilast and Placebo in Fragile X Syndrome, sponsored by Tetra Discovery Partners. Completed at 17 sites in United States. Open to male participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.
Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 12th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2022, is one of 5 in phase 2/3, and was the 65th registered.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
Browse Fragile X Syndrome studies →11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:
Healing Hope International · Sites in United States
Ages 4–12
Mirum Pharmaceuticals, Inc. · Sites in United States, Spain
Ages 13–45 · Men only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 5–10 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo–26 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 9 Years to 18 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 36 · Phase 3 11 · Phase 4 2
First in 2002; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Median enrollment 60 across the 68 interventional studies, 100 across the 12 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 82 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tetra Discovery Partners, one of the names counted as Shionogi. Under that name alone:
Tetra Discovery Partners is the lead sponsor of 9 studies on the registry; none are open to participants now.
Shionogi has 4 studies filed under Fragile X Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Fragile X Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05367960Phase 3Tetra Discovery PartnersAn Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | 2027-09-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06560242Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant | 2027-03-01 |
| NCT05957549Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Fragile X Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to \< 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).
In amendment 4 the enrollment age range what changed to allow enrollment in participants as young as 9 years of age. This only affects Part 2 as Part 1 was completed prior to this amendment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Patient is male adolescent aged 9 to \< 18 years. 2. Patient has FXS with a molecular genetic confirmation of the full fragile X mental retardation-1 (FMR1) mutation (≥ 200 CGG repetitions).
3. Current treatment with ≤ 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications. If the subject is on 3 prescribed psychoactive medications and, in addition, is taking either a psychoactive over-the-counter medication (eg, melatonin, Benadryl, etc.) or CBD products, the investigator is encouraged to discuss eligibility with the medical monitor.
4. Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.
5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks before screening and must remain stable during the period between screening and the commencement of study drug. Every effort should be made to keep dosing stable throughout the study.
6. Patients with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months before screening or must be seizure-free for 2 years if not currently receiving anti-epileptics.
7. Behavioral and other non-pharmacological treatments/interventions must be stable for 4 weeks before screening and must remain stable during the period between screening and the commencement of study drug, and throughout the study. Minor changes in hours or times of therapy that are not considered will not be exclusionary. Changes in therapies provided through a school program, due to school vacations, are allowed.
8. Patient must be willing to practice barrier methods of while on study, if sexually active. Abstinence is also considered a reasonable form of birth control in this study population.
9. Patient has a parent(s), legal authorized guardian(s), or consistent caregiver(s).
10. Patient and caregiver are able to attend the clinic regularly and reliably. 11. Patient's parent(s), legal authorized guardian(s), or consistent caregiver(s) is able to understand and sign an form to participate in the study.
12. Patient must provide assent for participation in the study if the patient has the cognitive ability to provide assent.
13. To participate in the Part 1 PK only: subjects must be able to swallow capsules.
Exclusion Criteria:
Diagnosis and main criteria for inclusion:
The eligibility criteria are the same for all parts of the study except for Part 1 (PK), where patients must be able to swallow capsules and must weigh at least 75 lbs (34 kg) to receive the 50 mg dose.
Patient Inclusion Criteria
Patient Exclusion Criteria
History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal, psychiatric, neurologic, cerebrovascular, or other systemic disease that would place the patient at risk or potentially interfere with the interpretation of the safety, tolerability, or efficacy of the study drug.
Patient has participated in another clinical trial within the 30 days before screening.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 15 mg BID or 25mg BID dose of BPN14770
Drug: zatolmilast
Subjects will receive matching Placebo
Drug: Placebo
Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
Also known as: BPN14770
Placebo
NIH Toolbox Cognitive Battery cognition crystallized composite score
The change from baseline to Week 13 in the NIH Toolbox Cognitive Battery cognition crystallized composite score (NIH-TCB CCC), which is calculated from the Picture Vocabulary and Oral Reading domains.
Time frame: 13 Weeks
NRS patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.
Change from baseline to Week 13 in Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skills.
Time frame: 13 Weeks
CaGI-I for the general domains of Daily Function, Language, and Academic Skills.
Change from baseline to Week 13 Caregiver Global Impression of Improvement (CaGI-I) for the general domains of Daily Function, Language, and Academic Skills.
Time frame: 13 Weeks
Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills
Change from baseline to Week 13 Clinical Global Impression Improvement - Investigator rated (CGI-I) for the general domains of Daily Function, Language, and Academic Skills
Time frame: 13 Weeks
NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors
Change from baseline to Week 13 NRS scores based on patient-specific behaviors within the domain of Emotions/Behaviors
Time frame: 13 Weeks
CaGI-I for the general domain of Emotions/Behaviors
Change from baseline to Week 13 CaGI-I for the general domain of Emotions/Behaviors
Time frame: 13 Weeks
The NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed
Change from baseline to Week 13 the NIH-TCB domains of Picture Vocabulary, Oral Reading Recognition, and Pattern Comparison Processing Speed
Time frame: 13 Weeks
Vineland-3 Adaptive Behavior Scale (Vineland-3)
Change from baseline to Week 13 Vineland-3 Adaptive Behavior Scale (Vineland-3)
Time frame: 13 Weeks
Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment
Change from baseline Verbal Knowledge test from the Stanford Binet (ed 5) (SB-5) IQ assessment
Time frame: 13 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Sep 2025, 41 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BPN14770